Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Genomic medicine for inhabiting lung cancer transfer and pulmonary metastatic tumor

A technology for lung cancer metastasis and drugs, which is applied in gene therapy, anti-tumor drugs, drug combinations, etc., can solve the problems such as the inability to play the target organ tumor treatment purpose well, and the low concentration of anti-tumor angiogenesis factors.

Inactive Publication Date: 2011-10-12
刁勇 +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In addition, the studies on anti-tumor angiogenesis factor gene therapy all adopt the mode of systemic administration such as intramuscular injection and intravenous injection, and the concentration of anti-tumor angiogenesis growth factor generated in the target organ is low, which cannot better play the therapeutic purpose of target organ tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Genomic medicine for inhabiting lung cancer transfer and pulmonary metastatic tumor
  • Genomic medicine for inhabiting lung cancer transfer and pulmonary metastatic tumor
  • Genomic medicine for inhabiting lung cancer transfer and pulmonary metastatic tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Preparation of rAAV2 / 2-eGFP

[0074] The composition of the expression frame of the eGFP expression plasmid is as follows: the promoter is CMV enhancer / chicken β-actin promoter, eGFPcDNA, polyA, WPRE. The two ends of the expression box are AAV2ITR.

[0075] Prepare recombinant virus by calcium phosphate-free helper virus multi-plasmid method: co-transfect 293 cells with eGFP expression plasmid, AV helper plasmid, and rAAV2 helper plasmid, harvest cells after 60-72 hours, and use sodium deoxycholate (0.5%) Cleavage with benzonase (30u / m1), centrifugation (3000g 30min) to remove cell debris, cesium chloride gradient centrifugation to obtain the recombinant virus rAAV2 / 2-eGFP, and chromatographic purification.

Embodiment 2

[0077] rAAV2 / 1-eGFP, rAAV2 / 3-eGFP, rAAV2 / 4-eGFP, rAAV2 / 5-eGFP, rAAV2 / 6-eGFP, rAAV2 / 7-eGFP, rAAV2 / 8-eGFP, rAAV2 / 9-eGFP, rAAV2 / Preparation of 10-eGFP and rAAV2 / 11-eGFP

[0078] Referring to the steps in Example 1, the rAAV2 helper plasmids were replaced with rAAV1, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10, and rAAV11, and the remaining operations were the same as in Example 1 to obtain 11 different serotypes of rAAV viruses.

Embodiment 3

[0080] Screening for lung-tropic rAAV serotypes

[0081] The titers of the various serotypes of rAAV obtained in Example 2 were determined by Real-PCR method. The primers used were designed according to the sequence of WPRE, respectively WPRE-F (5'-TGGCGTGGTGTGCACTGT) and WPRE-R (5'-GTTCCGCCGTGGCAATAG).

[0082] LLC cells or HLEC cells were seeded into 24-well plates and cultured overnight. Add the various serotype rAAV viruses that contain embodiment 2 and obtain respectively (MOI 10 4 ) serum-free medium, after incubation for 5 hours, it was replaced with normal medium. After 72 hours, the cells were observed with a fluorescent microscope, and the cells were sorted with a flow cytometer, and the transduction efficiency was calculated (n=3).

[0083] Table 3 Transduction efficiency of different serotypes of rAAV to LLC cells or HLEC cells

[0084] rAAV serotype

[0085] It can be seen that the transduction efficiency of various serotypes of rAAV to LLC cells or ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides genomic medicine for inhabiting lung cancer transfer and pulmonary metastatic tumor, which relates to the fields of molecular pharmacology, molecular medical science and disease prevention and treatment, in particular to the genomic medicine for generating inhabiting genes on the basis of recombinant adeno-associated viruses (rAAV) and tumor vessels. The medicine can act onthe lung tissue in a target way, and can effectively inhabit the transfer of the lung cancer and the occurrence of the pulmonary metastatic tumor.

Description

technical field [0001] The present invention relates to the fields of molecular pharmacology, molecular medicine and disease prevention and treatment, in particular to a gene drug based on recombinant adeno-associated virus (rAAV) and tumor angiogenesis inhibitory gene, which can target lung tissue and effectively inhibit the metastasis of lung cancer and lung metastases. Background technique [0002] Primary bronchial lung cancer (abbreviated as lung cancer) is the most common primary malignant tumor of the lung. It ranks first in the statistics of the incidence of tumors and the mortality of patients due to tumors in the world, accounting for about 18% of the total number of cancer patients. Currently, there are many clinically used drugs for the treatment of lung cancer, including paclitaxel (paclitaxel), a topoisomerase II inhibitor, etoposide (etoposide), a platinum compound, carboplatin, and docetaxel. (docetaxel) etc. are used in the treatment of non-small cell lung ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61P11/00A61P35/00A61P35/04C12N15/12C12N15/86
Inventor 刁勇许瑞安蔡克霞
Owner 刁勇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com